Cardiovascular Clinical Research Center, Division of Cardiology, New York University School of Medicine, New York, New York, USA.
Am J Cardiol. 2012 Oct 1;110(7):954-60. doi: 10.1016/j.amjcard.2012.05.024. Epub 2012 Jun 22.
Renal dysfunction is an independent predictor of cardiovascular events and a negative prognostic indicator after myocardial infarction (MI). Randomized data comparing percutaneous coronary intervention to medical therapy in patients with MI with renal insufficiency are needed. The Occluded Artery Trial (OAT) compared optimal medical therapy alone to percutaneous coronary intervention with optimal medical therapy in 2,201 high-risk patients with occluded infarct arteries >24 hours after MI with serum creatinine levels ≤2.5 mg/dl. The primary end point was a composite of death, MI, and class IV heart failure (HF). Analyses were carried out using estimated glomerular filtration rate (eGFR) as a continuous variable and by eGFR categories. Long-term follow-up data (maximum 9 years) were used for this analysis. Lower eGFR was associated with development of the primary outcome (6-year life-table rates of 16.9% for eGFR >90 ml/min/1.73 m(2), 19.2% for eGFR 60 to 89 ml/min/1.73 m(2), and 34.9% for eGFR <60 ml/min/1.73 m(2); p <0.0001), death, and class IV HF, with no difference in rates of reinfarction. On multivariate analysis, eGFR was an independent predictor of death and HF. There was no effect of treatment assignment on the primary end point regardless of eGFR, and there was no significant interaction between eGFR and treatment assignment on any outcome. In conclusion, lower eGFR at enrollment was independently associated with death and HF in OAT participants. Despite this increased risk, the lack of benefit from percutaneous coronary intervention in the overall trial was also seen in patients with renal dysfunction and persistent occlusion of the infarct artery in the subacute phase after MI.
肾功能障碍是心血管事件的独立预测因子,也是心肌梗死 (MI) 后的负面预后指标。需要随机数据比较经皮冠状动脉介入治疗与肾功能不全 MI 患者的药物治疗。闭塞动脉试验 (OAT) 比较了单独最佳药物治疗与经皮冠状动脉介入治疗加最佳药物治疗在 2201 例 MI 后 24 小时以上血清肌酐水平 ≤2.5mg/dl 的闭塞梗死动脉高风险患者中的疗效。主要终点是死亡、MI 和 IV 级心力衰竭 (HF) 的综合结果。分析采用估计肾小球滤过率 (eGFR) 作为连续变量和 eGFR 分类进行。该分析使用长期随访数据 (最长 9 年)。较低的 eGFR 与主要结局的发展相关 (eGFR >90ml/min/1.73m2 的 6 年生命表发生率为 16.9%,eGFR 为 60 至 89ml/min/1.73m2 的发生率为 19.2%,eGFR <60ml/min/1.73m2 的发生率为 34.9%;p<0.0001)、死亡和 IV 级 HF,再梗死率无差异。多变量分析显示,eGFR 是死亡和 HF 的独立预测因子。无论 eGFR 如何,治疗分配对主要终点均无影响,eGFR 与治疗分配之间在任何结局上均无显著交互作用。总之,OAT 参与者在登记时较低的 eGFR 与死亡和 HF 独立相关。尽管风险增加,但在整个试验中,肾功能不全和 MI 后亚急性期梗死动脉持续闭塞的患者也没有从经皮冠状动脉介入治疗中获益。